vorinostat has been researched along with Cancer of Intestines in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In early-phase studies with targeted therapeutics and radiotherapy, it may be difficult to decide whether an adverse event should be considered a dose-limiting toxicity (DLT) of the investigational systemic agent, as acute normal tissue toxicity is frequently encountered with radiation alone." | 2.76 | Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. ( Bratland, A; Dueland, S; Flatmark, K; Hollywood, D; Ree, AH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bratland, A | 1 |
| Dueland, S | 1 |
| Hollywood, D | 1 |
| Flatmark, K | 1 |
| Ree, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.[NCT00455351] | Phase 1 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Cancer of Intestines
| Article | Year |
|---|---|
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Tract; H | 2011 |
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Tract; H | 2011 |
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Tract; H | 2011 |
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Tract; H | 2011 |